Belvarafenib NEW
| Price | $58 | $103 | $173 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-27 |
Product Details
| Product Name: Belvarafenib | CAS No.: 1446113-23-0 |
| Purity: ≥98% | Supply Ability: 10g |
| Release date: 2025/04/27 |
Product Introduction
Bioactivity
| Name | Belvarafenib |
| Description | Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM. |
| In vitro | Belvarafenib (HM95573) inhibited B-RAF, B-RAFv600E and C-RAF with IC50 values of 56, 7 and 5 nM, respectively.[1] |
| In vivo | METHODS: Data were collected from 192 patients with melanoma who underwent NGS between November 2017 and May 2023.EAP patients were treated with 450 mg of Belvarafenib (HM95573) twice daily. RESULTS Six patients with NRAS or RAF alterations were treated with Belvarafenib (HM95573), and 50% of the patients had control of their disease, including two patients with significant outcomes. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 25 mg/mL (52.2 mM), Sonication is recommended. |
| Keywords | RG-6185 | RG6185 | RG 6185 | Raf kinases | Raf | Inhibitor | inhibit | HM-95573 | HM95573 | HM 95573 | GDC-5573 | GDC5573 | GDC 5573 | Belvarafenib |
| Inhibitors Related | Regorafenib monohydrate | Exarafenib | Doramapimod | Sulindac sulfide | Sorafenib | Regorafenib | Dabrafenib | Sorafenib tosylate | PLX-4720 | LY3009120 | Pelitinib | GW 441756 |
| Related Compound Libraries | Apoptosis Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1280.00/200mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-04-27 | |
| $8.00/1kg |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-03-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY